Screener
CytomX Therapeutics CTMX Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
FAQ
- What is CytomX Therapeutics's operating lease liabilities (current)?
- CytomX Therapeutics (CTMX) reported operating lease liabilities (current) of $1.5M in Q2 2026.
- How has CytomX Therapeutics's operating lease liabilities (current) changed year-over-year?
- CytomX Therapeutics's operating lease liabilities (current) decreased by 72.5% year-over-year, from $5.44M to $1.5M.
- What is the long-term trend for CytomX Therapeutics's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), CytomX Therapeutics's operating lease liabilities (current) has grown at a 5.8% compound annual growth rate (CAGR), from $3.2M to $4.24M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.
Ask your AI about CytomX Therapeutics's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude